Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives -: II.: The combination of amino acid residues in the dipeptidic moiety and its effect on the anti-Helicobacter pylori activity

被引:4
作者
Hasuoka, A
Nishikimi, Y
Nakayama, Y
Kamiyama, K
Nakao, M
Miyagawa, K
Nishimura, O
Fujino, M
机构
[1] Takeda Chem Ind Ltd, Div Pharmaceut Res, Med Chem Res Labs 1, Yodogawa Ku, Osaka 5328686, Japan
[2] Takeda Chem Ind Ltd, Vaccine Grp, Mkt Div, Chuo Ku, Osaka 5408645, Japan
[3] Takeda Chem Ind Ltd, Pharmaceut Discovery Ctr, Div Pharmaceut Res, Yodogawa Ku, Osaka 5328686, Japan
[4] Takeda Chem Ind Ltd, Div Pharmaceut Res, Tsukuba, Ibaraki 3004293, Japan
关键词
D O I
10.7164/antibiotics.55.499
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
The novel natural antibiotics pyloricidin A, B and C, consisting of a common (2S,3R,4R,5S)-5-amino-2,3,4,6-tetrahydroxyhexanoyl-beta-D-phenylalanine moiety and a terminal peptidic moiety (pyloricidin A: L-valine-L-valine-L-leucine; pyloricidin 13: L-valine-L-leucine; pyloricidin C: L-leucine), exhibit potent and highly selective anti-Helicobacter pylori activity. In order to develop more potent compounds and to investigate structure activity relationships for the peptidic moiety with regard to the combination of amino acids, a series of derivatives with various dipeptidic moieties were prepared and evaluated for their anti-H. pylori activity. The combination or the two amino acids in the moiety was found to have a significant effect on the activity the compound with Nva-Abu showed excellent anti-H. pylori activity with an MIC value of 0.013 mug/ml against H. pylori TN2. In addition, this compound was found to show 60% clearance of H. pylori from infected Mongolian gerbils upon repetitive oral administration (10 mg/kg, b. i. d. for 7 days).
引用
收藏
页码:499 / 507
页数:9
相关论文
共 16 条
[1]   ULCERS AS AN INFECTIOUS-DISEASE [J].
ALPER, J .
SCIENCE, 1993, 260 (5105) :159-160
[2]   Eradication of Helicobacter pylori [J].
Axon, ATR .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 :47-53
[3]   SHORT-TERM LOW-DOSE TRIPLE THERAPY FOR THE ERADICATION OF HELICOBACTER-PYLORI [J].
BAZZOLI, F ;
ZAGARI, RM ;
FOSSI, S ;
POZZATO, P ;
ALAMPI, G ;
SIMONI, P ;
SOTTILI, S ;
RODA, A ;
RODA, E .
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 1994, 6 (09) :773-777
[4]   Helicobacter pylori and peptic ulcer disease [J].
Blum, AL .
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 1996, 31 :24-27
[5]  
CHIBA N, 1992, AM J GASTROENTEROL, V87, P1716
[6]   Susceptibility of Helicobacter pylori isolates against agents commonly administered for eradication therapy and the efficacy of chemotherapy [J].
Gotoh, A ;
Kawakami, Y ;
Akahane, T ;
Akamatsu, T ;
Shimizu, T ;
Kiyosawa, K ;
Katsuyama, T .
MICROBIOLOGY AND IMMUNOLOGY, 1997, 41 (01) :7-12
[7]   TREATMENT OF PEPTIC-ULCERS CAUSED BY HELICOBACTER-PYLORI [J].
GRAHAM, DY .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (05) :349-350
[8]   Total synthesis of novel antibiotics pyloricidin A, B and C and their application in the study of pyloricidin derivatives [J].
Hasuoka, A ;
Nishikimi, Y ;
Nakayama, Y ;
Kamiyama, K ;
Nakao, M ;
Miyagawa, K ;
Nishimura, O ;
Fujino, M .
JOURNAL OF ANTIBIOTICS, 2002, 55 (02) :191-203
[9]   Synthesis and anti-Helicobacter pylori activity of pyloricidin derivatives -: I.: Structure-activity relationships on the terminal peptidic moiety [J].
Hasuoka, A ;
Nishikimi, Y ;
Nakayama, Y ;
Kamiyama, K ;
Nakao, M ;
Miyagawa, KI ;
Nishimura, O ;
Fujino, M .
JOURNAL OF ANTIBIOTICS, 2002, 55 (03) :322-336
[10]   Anti-Helicobacter pylori agents.: 4.: 2-(Substituted guanidino)-4-phenylthiazoles and some structurally rigid derivatives [J].
Katsura, Y ;
Tomishi, T ;
Inoue, Y ;
Sakane, K ;
Matsumoto, Y ;
Morinaga, C ;
Ishikawa, H ;
Takasugi, H .
JOURNAL OF MEDICINAL CHEMISTRY, 2000, 43 (17) :3315-3321